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Extracorporeal membrane oxygenation (ECMO) is a widely used therapy for neonates with respiratory
failure. Because of sepsis, many of these infants require antibiotics like vancomycin during ECMO treatment.
ECMO transiently alters renal function and increases the circulating blood volume by 75%. Initial vancomycin
pharmacokinetics were determined in 12 infants undergoing ECMO to determine an adequate drug admin-
istration regimen. Vancomycin dosage was based on current recommendations for weight and gestational age.
Pharmacokinetic parameters were determined by fitting the data to a two compartment model. This study
yielded a mean steady-state volume of distribution of 1.1 6 0.5 (range, 0.6 to 2.1) liters/kg and a mean
vancomycin clearance of 0.78 6 0.19 (range, 0.49 to 1.07) ml/min/kg. The mean vancomycin half-life was 16.9
6 9.5 (range, 8.8 to 42.9) h. Nomogram-calculated creatinine clearance was a significant predictor of vanco-
mycin terminal rate constant and clearance. These data suggest alterations in the pharmacokinetics of
vancomycin in infants on ECMO. With the goal of achieving vancomycin concentrations in serum above the
MIC for the offending pathogen while using the least amount of the drug necessary, new administration
guidelines for term infants without renal impairment undergoing ECMO should be 20 mg of vancomycin per
kg at an interval of 24 h. With significant renal impairment, the interval should be extended on the basis of
concentrations in serum. In comparison with previously published data, the neonates undergoing ECMO in
our study demonstrated a much larger volume of distribution, a lower clearance, and consequently a longer
vancomycin half-life.
Extracorporeal membrane oxygenation (ECMO) is a
method of cardiopulmonary bypass used to rescue term neo-
nates with respiratory failure (4). ECMO has improved sur-
vival from 20 to 80% in a select group of infants with nearly
fatal but ultimately reversible pulmonary hypertension (1, 17).
Venoarterial ECMO is accomplished by removing blood from
the jugular vein, passing it through a membrane oxygenator,
and then pumping it back into the aortic arch through the
carotid artery. Because ECMO increases the circulating blood
volume and transiently alters renal function, it is reasonable to
assume that it likewise alters drug pharmacokinetics. In adult
cardiopulmonary bypass, it is known that half-life (t1/2) is pro-
longed, clearance (CL) is decreased, and volume of distribu-
tion (V) is increased for many drugs (10). These changes have
not been demonstrated for vancomycin in children undergoing
bypass for cardiopulmonary surgery (8). The few studies that
have been done on infants undergoing ECMO defined the
pharmacokinetics of gentamicin. Southgate et al. (19) reported
an increase in gentamicin t1/2 from 5 h in non-ECMO-treated
infants to 9.3 h in infants on ECMO. Gentamicin CL was
decreased. Gentamicin pharmacokinetics altered by ECMO
have been confirmed by other investigators (5, 7). With the
emergence of methicillin-resistant staphylococci as an ever-
present pathogen, many infants receive vancomycin. This study
was designed to determine the pharmacokinetics of vancomy-
cin in infants undergoing ECMO. With these data, revised
recommendations for vancomycin administration to ECMO
patients were derived.
(This report was presented at the Southern Society for Pe-
diatric Research Meetings, 3 to 5 February 1995, in New Or-
leans, La.)
MATERIALS AND METHODS
All neonates at the Medical College of Georgia who were undergoing ECMO
and had been started on vancomycin for clinical indications were eligible for this
study. This study was approved by the Human Assurance Committee at the
Medical College of Georgia, and infants were enrolled after informed parental
consent was obtained. From January 1994 to March 1995, 12 infants were pro-
spectively enrolled into the study. All 12 of these infants underwent venoarterial
ECMO.
The extracorporeal circuit consisted of arterial and venous cannulae (Biomed-
icus cannulas; Medtronics Biomedicus, Inc., Eden Prairie, Minn.), extracorporeal
tubing (Tygon 5-50-HL or Super Tygon 5-65-HL; Norton, Akron, Ohio), a
venous reservoir (35-ml capacity R-14 silicone; Avecor Cardiovascular, Inc.,
Plymouth, Minn.), a membrane oxygenator (Avecor model 0800-2A; Avecor
Cardiovascular Inc.), and a heat exchanger (Ecmotherm; Avecor Cardiovascular,
Inc.), and the total blood volume was approximately 400 ml.
Vancomycin hydrochloride (Lederle, Inc., Carolina, Puerto Rico) was given at
either 15 or 20 mg/kg (intravenously over a 1-h period) at intervals of either 8, 12,
or 18 h on the basis of gestational age. Vancomycin was infused for 1 h into the
circuit at a point distal to the venous reservoir. Blood samples (0.3 ml) were
collected from the venous cannula at a point proximal to the venous reservoir.
Samples were drawn over the administration interval after the fourth dose from
11 infants and after the third dose from 1 of the infants because of early
decannulation. Drug concentrations were determined immediately before and at
15, 30, 60, and 120 min following completion of the dose infusion. The remaining
three concentrations were determined at evenly spaced intervals over the re-
mainder of the administration interval. Drug concentrations in serum were
determined by fluorescence polarization immunoassay (TDX System; Abbott
Laboratories, Abbott Park, Ill.). The assay is linear from 2 to 100 mg/ml (corre-
lation coefficient, 0.957) with coefficients of variation of ,6% at 7.0 mg/ml and
,4% at 35 and 75 mg/ml. The lowest measurable level (defined as the concen-
tration which can be distinguished from zero with 95% confidence) was deter-
mined to be 2 mg/ml.
Serum creatinine and blood urea nitrogen levels were determined every 12 h
during ECMO. Demographic data recorded for each subject consisted of gesta-
tional age, birth weight, birth length, and gender. In addition, diagnosis, age
when placed on ECMO, hours on ECMO, and outcome were recorded for each
infant. Outcome was defined as death or survival. Survival was defined as survival
until the time of hospital discharge.
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Analysis of data. For each subject, drug concentrations were fitted to a two-
compartment, multiple-dose infusion model without weighting (Rstrip; Micro-
math, Salt Lake City, Utah). For all models, the model selection criterion (mod-
ified Akaike information criterion) was between 2.3 and 6.4 (mean, 4.0). For 11
of 12 subjects, the model selection criterion for the two-compartment model was
greater than that for a one-compartment model. No subject had a model selec-
tion criterion for a three-compartment model that was greater than that for a
one- or two-compartment model. The terminal elimination rate constant (b) was
determined from the logarithmic slope of the terminal portion of the drug
concentration-versus-time plot. The drug t1/2 was determined by the equation t1/2
5 0.693/b. Vancomycin CL was calculated by the equation CL 5 dose/AUC,
where AUC is the area under the serum concentration-time curve for the ad-
ministration interval at steady state. The AUC was calculated from the sum of
intercepts divided by the slopes for the model parameters with AUCs for the last
time point to infinity subtracted. V was calculated by the equation V 5 dose/
(AUC z b). By using the pharmacokinetic parameters and a simple one-compart-
ment model, an optimal dose and interval were calculated for each subject to
achieve a peak concentration of 30 mg/ml and a trough of 5 to 10 mg/ml. The drug
administration interval was determined from the equation t0 5 [ln(Ctrough/
Cpeak)]/2b, where t0 5 interval 2 (infusion time 1 time from end of infusion
until peak). The dose was calculated by using a one-compartment monoexpo-
nential model by the equation Dose 5 Cpeak 3 b 3 V 3 (1 2 e2bt)/(1 2 e2bt)
3 (e2bT), where t is the drug administration interval, T is the time after infusion
until a peak is drawn, and t is the infusion time. In clinical practice, vancomycin
is infused over a 1-h period and the peak concentration is determined 1 h after
the end of the infusion. From a clinical standpoint, individual dosage and interval
values can be determined from the terminal elimination phase of the concen-
tration-versus-time curve. For this reason, a one-compartment model is appro-
priate for prediction of the dosage and interval by using b as the elimination rate
constant.
Statistical analysis. Creatinine CL was estimated from serum creatinine for
each patient by using the Schwartz equation (18). Linear regression analyses
(Statgraphics; STSC, Rockville, Md.) were used to test for significant relation-
ships between pharmacokinetic parameters and creatinine CL, gestational age,
chronologic age, and birth weight. Multiple regression analysis was used to
combine all significant relationships as possible predictors of pharmacokinetic
parameters. Standard statistical methods were used to describe demographic
data.
RESULTS
Twelve term infants were enrolled in the study, and nine
survived. The mean estimated gestational age was 39 weeks, 6
1.4 (standard deviation) and the mean birth weight was 3.3 6
0.4 kg. Half (six) of the infants had documented sepsis. Nine
infants had persistent pulmonary hypertension, and three had
respiratory distress syndrome. The infants demonstrated a
wide range of serum creatinine levels at the time of data
collection, from 0.6 to 1.9 mg/dl. Four infants in this cohort had
serum creatinine levels of .1.5 mg/dl. Demographic data for
the group are presented in Table 1.
Pharmacokinetics. The mean serum drug concentration-ver-
sus-time elimination curve is shown in Fig. 1. The mean phar-
macokinetic parameters for the entire group of 12 subjects are
as follows: terminal t1/2, 16.9 6 9.54 (range, 8.8 to 42.9) h; CL,
0.786 0.19 (range, 0.49 to 1.07) ml/min/kg; V, 1.16 0.5 (range,
0.6 to 2.1) liters/kg. Data for the entire cohort are shown in
Table 2. Minus the four subjects with elevated serum creati-
nine levels (.1.5 mg/dl), the mean pharmacokinetic parame-
ters for those eight subjects with serum creatinine levels of
,1.5 mg/dl are as follows: terminal t1/2, 13.2 6 4.5 (range, 8.8
to 20.4) h; CL, 0.87 6 0.14 (range, 0.64 to 1.07) ml/min/kg; V,
0.996 0.35 (range, 0.56 to 1.5) liter/kg. Mean pharmacokinetic
data of the eight subjects with serum creatinine levels of ,1.5
mg/dl are compared to those of the four subjects with serum
creatinine levels of .1.5 mg/dl in Table 3. Linear regression
analyses of the entire cohort revealed that creatinine CL esti-
mated from serum creatinine levels was a predictor of b (r2 5
FIG. 1. Mean vancomycin concentration-versus-time data for cohort serum
samples. Error bars represent standard deviations.
TABLE 1. Patient demographic data
Infant no. Diagnosisa Birth wt(kg)
Gestational
age (wks) Gender
b Age (h) when
put on ECMO
Time on
ECMO (h)
Serum creatinine
(mg/dl) Outcome
c
1 PPHN, sepsis 2.84 38 F 12 87 1.0 S
2 PPHN, MAS 3.64 39 F 152 129 0.8 D
3 PPHN, sepsis 3.34 37 M 60 96 1.0 S
4 PPHN, sepsis 2.93 39 M 11 42 1.8 D
5 PPHN, MAS 3.94 41 F 23 221 1.2 S
6 PPHN, sepsis 3.12 38 M 18 69 1.9 D
7 RDS 2.95 38 M 18 66 1.8 S
8 PPHN, sepsis 2.90 39 F 28 91 0.9 S
9 PPHN, MAS 2.73 42 F 54 56 0.7 S
10 RDS 3.58 38 M 41 86 0.6 S
11 PPHN, MAS 3.45 40 M 19 79 1.6 S
12 RDS, sepsis 3.94 39 F 20 88 0.8 S
Mean 6 SD 3.3 6 0.43 39 6 1.4 6 F, 6 M 386 39 93 6 46 1.18 6 0.47 9 S, 3 D
a PPHN, persistent pulmonary hypertension; MAS, meconium aspiration syndrome; RDS, respiratory distress syndrome.
b F, female; M, male.
c S, survival; D, death.
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0.41; P 5 0.023; correlation coefficient, 0.647) (Fig. 2). Simi-
larly, estimated creatinine CL was a strong predictor of van-
comycin CL (r2 5 0.71; P5 0.003; correlation coefficient, 0.78)
(Fig. 3). Vancomycin CL was positively correlated with chro-
nologic age (P 5 0.04; correlation coefficient, 0.59). V was
inversely related to gestational age (P 5 0.03; correlation co-
efficient,20.61). The relationship between vancomycin t1/2 and
gestational age did not reach statistical significance (P 5 0.08;
correlation coefficient, 20.51). Multiple regression analysis
demonstrated no factors which better predicted pharmacoki-
netic data than creatinine CL alone.
On the basis of these pharmacokinetic data, the intervals
needed to achieve a 1-h postinfusion peak drug concentration
of 30 mg/ml and a trough concentration of 5 to 10 mg/ml were
calculated. With the interval determined, the dosage per kilo-
gram of body weight was calculated for each subject. The
calculated drug administration regimen for each individual is
represented in Table 2.
DISCUSSION
Current vancomycin administration recommendations for
infants originated from studies which included both premature
and term infants (11, 13, 14, 16). Gestational age, postnatal
age, and body weight have all been shown to affect the phar-
macokinetics of vancomycin. Two studies of vancomycin phar-
macokinetics have been done with non-ECMO-treated new-
borns 40 to 41 weeks in gestational age, a uniform population
with a mean gestational age similar to that of a typical ECMO
population. Schaad et al. (16) demonstrated a t1/2 of 6.7 h, a CL
of 1.18 ml/min/kg, and a V of 0.69 liter/kg. Similarly, Naqvi et
al. (14) reported a t1/2 of 4.87 h, a CL of 1.34 ml/min/kg, and a
V of 0.48 liter/kg. These values, therefore, represent usual
vancomycin pharmacokinetic parameters for term infants. It
should be emphasized that infants undergoing ECMO repre-
sent a subgroup of severely ill newborns, and a comparison of
this group to non-ECMO-treated newborns should be made
cautiously. Neonates undergoing ECMO in our study demon-
strated a much larger V, a lower CL, and consequently a longer
t1/2 of vancomycin. These alterations of vancomycin pharma-
cokinetics are consistent with, but much more pronounced
than, those previously reported for gentamicin in infants un-
dergoing ECMO (19).
There has been only one prospective investigation of vanco-
mycin pharmacokinetics in neonates undergoing ECMO ther-
apy. Hoie et al. (9) reported the following data for six infants
undergoing ECMO: t1/2, 7.71 h; CL, 1.10 ml/min/kg; V, 0.68
liter/kg. These data were derived with a one-compartment
model from three of the subjects, which could have artificially
decreased the t1/2 measurements. In addition, no infants with
serum creatinine levels of .1.5 mg/dl were included in this
study. Nonetheless, t1/2 and V were increased, although to a
lesser extent than in our study. Reasons for these differences
are not clear.
As with adult cardiopulmonary bypass, it is reasonable to
assume that ECMO causes a large dilution of plasma, which
can result in a larger V for most drugs. For a 4-kg infant, an
additional 120 ml of extracellular fluid volume from the
ECMO circuit could represent an extracellular fluid volume
increase of 10%. In addition, there are large extracellular fluid
shifts in any critically ill neonate which could contribute to a
variable V at any given time. Immediate increases in extracel-
lular fluid have been demonstrated in neonates undergoing
ECMO (2). Often, decreased urine output and/or decreased
venous return to the circuit is ameliorated by repeated boluses
FIG. 2. Vancomycin b versus nomogram-calculated creatinine CL in each
subject (correlation coefficient, 0.65; r2 5 0.41; P 5 0.023).
TABLE 2. Pharmacokinetic data and optimal dose and interval calculated for the 12 infants in this study
Infant no. t1/2 (h) CL (ml/min/kg) V (liters/kg) Optimal dose (mg/kg) Optimal interval (h) Serum creatinine (mg/dl)
1 20.4 0.91 1.5 32.5 36 1.0
2 14.7 1.07 1.4 34.1 30 0.8
3 19.3 0.76 1.3 29.8 36 1.0
4 13.1 0.80 0.9 24.9 24 1.8
5 9.5 0.64 0.6 15.1 24 1.2
6 42.9 0.58 2.1 44.1 72 1.9
7 24.8 0.49 1.2 27.6 60 1.8
8 11.4 0.84 0.8 21.1 24 0.9
9 8.8 0.98 0.7 18.7 18 0.7
10 10.8 0.93 0.9 22.5 24 0.6
11 16.4 0.49 0.7 17.4 36 1.6
12 10.9 0.81 0.8 19.8 24 0.8
Mean 6 SD 16.9 6 9.5 0.78 6 0.19 1.06 6 0.45 1.18 6 0.45
TABLE 3. Comparison of vancomycin pharmacokinetic parameters
for ECMO-treated patients with serum creatinine levels above and
below 1.5 mg/dl
Serum creatinine
level (mg/dl)
No. of
infants
Mean t1/2
(h) 6 SD
Mean CL
(ml/min/kg)
6 SD
Mean V
(liters/kg)
6 SD
.1.5 4 24.24 6 13.39 0.59 6 0.15 1.22 6 0.63
,1.5 8 13.22 6 4.45 0.87 6 0.14 0.99 6 0.35
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of colloid and crystalloid, further causing changes in the vol-
ume status.
Vancomycin t1/2 is prolonged in premature infants because
of a decreased glomerular filtration rate (GFR) (15). Since the
GFR increases with gestational age as the kidneys mature (3),
there still may be a slight difference between the GFRs of
infants with gestational ages of 37 versus 42 weeks. Variations
in drug pharmacokinetics can be due in part to subtle differ-
ences in GFR as determined by gestational age in a group of
term infants. This relationship tended toward statistical signif-
icance in our cohort, with t1/2 inversely related to gestational
age. In addition, renal function in infants on ECMO is often
decreased, as evidenced by decreased urine output and tran-
sient rise and fall of creatinine (6). These changes are due not
only to periods of ischemia and decreased organ perfusion but
also to the nonpulsatile blood flow of the ECMO circuit. It has
long been known that nonpulsatile flow in dogs causes de-
creased urine output and sodium excretion, although GFR has
not been shown to be directly affected (12). Since vancomycin
is cleared primarily by renal excretion, the prolonged t1/2 and
decreased CL which we have demonstrated most likely reflect
renal injury with a decreased GFR, regardless of the mecha-
nism. In this population, we have shown that both t1/2 and drug
CL are strongly correlated with estimated creatinine CL, as
expected.
Individual dosages and intervals must therefore be arrived at
by careful consideration of renal function. Previously, Hoie et
al. (9) had recommended a vancomycin dose of 20 mg/kg at an
18-h interval for infants on ECMO with serum creatinine levels
of ,1.5 mg/dl. Our data indicate that infants on ECMO with
serum creatinine levels of ,1.5 mg/dl should be given vanco-
mycin no more frequently than every 24 h. In two of these eight
infants, even a 24-h interval would have produced trough con-
centrations of 13.5 and 14 mg/ml, respectively. The ideal dos-
age for this population is between 20 and 25 mg/kg. For the
four infants with serum creatinine levels of .1.5 mg/dl, the
proper intervals ranged from 24 to 72 h and the ideal dosage
remained roughly the same. On the basis of these data, we
recommend an initial dose of 20 mg/kg and an administration
interval of 24 h for infants on ECMO without significant renal
impairment. For infants on ECMO with significant renal im-
pairment (serum creatinine levels of .1.5 mg/dl) who require
vancomycin therapy, we recommend an initial one-time dose
of 20 mg/kg. Drug concentrations in serum should then be
determined at 12 and 24 h after the one-time dose so that an
individual administration regimen can be derived for each pa-
tient. A patient with renal failure could then be given another
dose when the concentration is calculated to fall below 10
mg/ml of serum.
In summary, ECMO appears to alter vancomycin pharma-
cokinetics by decreasing drug CL and therefore prolonging the
t1/2 by up to 100% compared with published reports on non-
ECMO-treated infants. V is increased 50% above that of non-
ECMO-treated infants. Estimated creatinine CL is strongly
correlated with both drug CL and b and can be used to predict
the appropriate vancomycin dosage and interval.
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FIG. 3. Vancomycin CL versus nomogram-calculated creatinine CL in each
subject (correlation coefficient, 0.78; r2 5 0.71; P 5 0.003).
1142 AMAKER ET AL. ANTIMICROB. AGENTS CHEMOTHER.
